Drug carrier-assisted combined chemo- and radionuclide therapy for tumors of diverse origins: effects of therapeutic schemes on tumor responses

作者：Alisa S. Postovalova, Darya R. Akhmetova, Anna Rogova, К. В. Сивак, Nina V. Gavrilova, Yana Zabrodskaya, Vladislava A. Rusakova, Yulia A. Tishchenko, Sergei A. Shipilovskikh, Alexander S. Timin · 发表于：Biomaterials Science · 年份：2024 · DOI：10.1039/d4bm01228c · 被引用次数：5 · 研究领域：Medical Imaging and Pathology Studies、Radiopharmaceutical Chemistry and Applications、Sarcoma Diagnosis and Treatment

). In particular, the average therapeutic response was >35% for monotherapy and >60%-80% for combined therapy. Importantly, the therapeutic effect across the three tumor types followed the order B16-F10 >4T1 >CT26. Thus, this work systematically investigated the response of three tumor types to the applicability of single chemo- or radionuclide therapy and their combination.